Cambrex Corp. (NYSE:CBM) shares traded down 3% during mid-day trading on Friday . The stock traded as low as $44.14 and last traded at $44.19, with a volume of 116,778 shares. The stock had previously closed at $45.58.

Separately, Zacks Investment Research cut Cambrex Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, June 29th.

The stock has a 50-day moving average of $51.78 and a 200-day moving average of $46.28. The firm has a market capitalization of $1.43 billion and a price-to-earnings ratio of 22.43.

Cambrex Corp. (NYSE:CBM) last issued its earnings results on Thursday, July 28th. The company reported $0.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.09. The firm earned $118.22 million during the quarter, compared to analyst estimates of $114.85 million. During the same quarter in the previous year, the business posted $0.63 EPS. Cambrex Corp.’s revenue was up 10.9% compared to the same quarter last year. Equities analysts predict that Cambrex Corp. will post $2.55 earnings per share for the current year.

In related news, Director William B. Korb sold 3,420 shares of Cambrex Corp. stock in a transaction on Monday, July 11th. The stock was sold at an average price of $55.00, for a total value of $188,100.00. Following the transaction, the director now owns 23,982 shares in the company, valued at $1,319,010. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William B. Korb sold 8,000 shares of Cambrex Corp. stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $51.06, for a total value of $408,480.00. Following the completion of the transaction, the director now owns 25,304 shares in the company, valued at approximately $1,292,022.24. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. King Luther Capital Management Corp raised its position in Cambrex Corp. by 148.7% in the fourth quarter. King Luther Capital Management Corp now owns 333,130 shares of the company’s stock valued at $15,687,000 after buying an additional 199,165 shares during the period. Dimensional Fund Advisors LP raised its position in Cambrex Corp. by 3.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,589,449 shares of the company’s stock valued at $74,848,000 after buying an additional 47,279 shares during the period. Redwood Investments LLC raised its position in Cambrex Corp. by 28.9% in the fourth quarter. Redwood Investments LLC now owns 45,791 shares of the company’s stock valued at $2,156,000 after buying an additional 10,259 shares during the period. Bank of Montreal Can raised its position in Cambrex Corp. by 31.1% in the fourth quarter. Bank of Montreal Can now owns 31,339 shares of the company’s stock valued at $1,476,000 after buying an additional 7,431 shares during the period. Finally, Morgan Stanley raised its position in Cambrex Corp. by 27.9% in the fourth quarter. Morgan Stanley now owns 323,861 shares of the company’s stock valued at $15,250,000 after buying an additional 70,585 shares during the period.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.